TY - JOUR
T1 - Update on Treatment of Liver Metastases
T2 - Focus on Ablation Therapies
AU - Meyer, Jeffrey
AU - Toomay, Seth
PY - 2014/11/22
Y1 - 2014/11/22
N2 - There is substantial and growing interest in the use of local therapies to treat patients with metastatic cancer, especially those deemed to have “oligometastatic” disease. Much of the literature to date consists of reports on metastasectomy for liver and lung metastases. Non-surgical minimally or non-invasive treatments including thermal ablation, irreversible electroporation, and high-dose radiation therapy (stereotactic ablative radiation therapy) can also be used in the treatment of primary and secondary tumors, including in the treatment of liver metastases. In this review, we discuss the rationale for using these ablative treatments in the treatment of liver metastases including similarities and differences between them.
AB - There is substantial and growing interest in the use of local therapies to treat patients with metastatic cancer, especially those deemed to have “oligometastatic” disease. Much of the literature to date consists of reports on metastasectomy for liver and lung metastases. Non-surgical minimally or non-invasive treatments including thermal ablation, irreversible electroporation, and high-dose radiation therapy (stereotactic ablative radiation therapy) can also be used in the treatment of primary and secondary tumors, including in the treatment of liver metastases. In this review, we discuss the rationale for using these ablative treatments in the treatment of liver metastases including similarities and differences between them.
KW - Ablation
KW - Irreversible electroporation
KW - Liver metastases
KW - Radiofrequency ablation
KW - Stereotactic radiation
UR - http://www.scopus.com/inward/record.url?scp=84949134600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949134600&partnerID=8YFLogxK
U2 - 10.1007/s11912-014-0420-2
DO - 10.1007/s11912-014-0420-2
M3 - Review article
C2 - 25416314
AN - SCOPUS:84949134600
SN - 1523-3790
VL - 17
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 1
ER -